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Abstract Glibenclamide improves outcomes in rat models
of stroke, with treatment as late as 6 h after onset of ische-
mia shown to be beneficial. Because the molecular target of
glibenclamide, the sulfonylurea receptor 1 (Sur1)-regulated
NCCa-ATP channel, is upregulated de novo by a complex
transcriptional mechanism, and the principal pathophysio-
logical target, brain swelling, requires hours to develop, we
hypothesized that the treatment window would exceed 6 h.
We studied a clinically relevant rat model of stroke in which
middle cerebral artery occlusion (75% < reduction in LDF
signal ≤90%) was produced using an intra-arterial occluder.
Recanalization was obtained 4.5 h later by removing the
occluder. At that time, we administered recombinant tissue
plasminogen activator (rtPA; 0.9 mg/kg IV over 30 min).
Immunolabeling showed modest expression of Sur1 5 h
after onset of ischemia, with expression increasing 7- to
11-fold (P<0.01) by 24 h. Rats were administered either
vehicle or glibenclamide (10 μg/kg IP loading dose plus
200 ng/h by constant subcutaneous infusion) beginning 4.5
or 10 h after onset of ischemia. In rats treated at 4.5 or 10 h,
glibenclamide significantly reduced hemispheric swelling at
24 h from (mean ± SEM) 14.7±1.5% to 8.1±1.6% or 8.8±
1.1% (both P<0.01), respectively, and significantly reduced
48-h mortality from 53% to 17% or 12% (both P<0.01), and
improved Garcia scores at 48 h from 3.8±0.62 to 7.6±0.70
or 8.4±0.74 (both P<0.01). We conclude that, in a clinically
relevant model of stroke, the treatment window for gliben-





Glibenclamide confers protection in various rat models of
stroke, including non-lethal models of thromboembolic,
permanent and temporary (105 min) occlusion, as well as
models of malignant cerebral edema [21, 23, 25]. In these
models, protection is manifested as significant improve-
ments in edema, brain swelling, lesion size, white matter
preservation, neurological function and mortality. Beneficial
effects of glibenclamide have been reported independently
using in vitro and in vivo models of ischemia/hypoxia [15,
18].
In cerebral ischemia, the molecular target of glibencla-
mide is the sulfonylurea receptor 1 (Sur1)-regulated NCCa-
ATP channel. All members of the neurovascular unit upregu-
late the Sur1-regulated NCCa-ATP channel after ischemia.
However, its role in endothelial cell swelling, which con-
tributes to ischemia, and its role in dysfunction of inter-
endothelial tight junctions, which contributes to edema for-
mation and brain swelling, are particularly important for
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The Sur1-regulated NCCa-ATP channel is not constitutive-
ly expressed but is transcriptionally upregulated after onset
of ischemia. Recent work showed that the molecular mech-
anism responsible for transcriptional upregulation of the
channel in endothelium involves a two-step sequential gene
activation process [30]. Hypoxia first activates hypoxia
inducible factor 1, which results in transcriptional upregu-
lation of the transcription factor, specificity protein 1 (Sp1).
Upregulation of Sp1, in turn, results in transcriptional upre-
gulation of Sur1, which then goes on to form functional ion
channels that are transported to and inserted into the cell
membrane. This multistep mechanism involving sequential
gene activation, channel assembly and transport predicts
that a prolonged time would be required before the molec-
ular target of glibenclamide is in place. Moreover, the prin-
cipal pathophysiological target of glibenclamide, brain
swelling, requires hours to develop [13, 20]. As a result,
we hypothesized that the treatment window for glibencla-
mide would exceed 6 h.
Here, we tested the hypothesis that glibenclamide would
have a long treatment window in a clinically relevant rat
model of stroke. Middle cerebral artery occlusion (MCAo)
was produced using an intra-arterial occluder. Recanaliza-
tion was obtained by removing the occluder at 4.5 h, simu-
lating intra-arterial mechanical clot retrieval [6]. At the same
time, we administered rtPA at the latest time and at the dose
used in humans (0.9 mg/kg IV) [2, 9]. Briefly, we found that
this model was associated with high mortality and severe
neurological disability, and that glibenclamide administered
at either 4.5 or 10 h after onset of ischemia significantly
improved outcomes.
Methods
Rat Model of Stroke
All surgical procedures were approved by the Institutional
Animal Care and Use Committee of the University of Mary-
land. Male Wistar rats (250–275 g; Harlan, Indianapolis, IN)
were anesthetized (ketamine, 60 mg/kg, and xylazine,
7.5 mg/kg, IP) and allowed to breath spontaneously room
air supplemented with oxygen to maintain 90% < sO2 <
99% by pulse oximetry. The procedures for intra-arterial
MCAo via the cervical external carotid artery (ECA), for
monitoring laser Doppler flowmetry (LDF) signals over the
involved cortex, for monitoring blood gases, for implanting
mini-osmotic pumps with catheters for delayed start of
infusion, for post-operative recovery of the animals and for
necropsy to establish stroke-related death, have been de-
scribed [23, 25]. Compared to our previous reports, the
principal differences in the present study were that: (1) we
used commercially available intra-arterial occluders
(0.39 mm; catalogue #4039PK5Re; Doccol Corp, Redlands
CA); (2) the rats were re-anesthetized at ~4 h to acquire IV
access via the external jugular vein, to remove the occluder
at 4.5 h, to ligate the stump of the ECA, and to implant a
mini-osmotic pump subcutaneously; (3) after removing the
occluder, an infusion of rtPA [Cathflo Activase (Alteplase),
Genetech, Inc., San Francisco, CA], 0.9 mg/kg IV over
30 min, was started; (4) at the time designated for treatment
(4.5 or 10 h after onset of ischemia), rats received either
vehicle or glibenclamide (10 μg/kg IP loading dose plus
start of constant subcutaneous infusion of 200 ng/h for
48 h). The low dose of glibenclamide used here has been
shown repeatedly not to cause hypoglycemia [21, 24, 25].
Blood gases immediately prior to MCAo were (mean ±
SD): pO2, 147±18 mmHg; pCO2, 56±1 mmHg and pH,
7.29±0.01; glucose, 135±7; Hct, 46±1; sO2, 97±1; pO2,
149±23 mmHg; pCO2, 57±1 mmHg and pH, 7.30±0.01;
glucose, 126±6; Hct, 46±1; sO2, 96±1; for vehicle vs.
glibenclamide treated rats, respectively.
LDF signals were monitored during the 30 min following
positioning of the MCA occluder. For the three groups (vehi-
cle, 4.5- and 10-h glibenclamide), LDF signals were reduced
by (mean ± SEM): 84.5±0.7%, 81.6±2.1%, and 83.7±1.2%,
respectively, which were not significantly different from each
other (by analysis of variance [ANOVA], P00.3).
Drug Formulation and Pump Preparation
A stock solution of glibenclamide was prepared by placing
25 mg glibenclamide (#G2539; meets USP testing; Sigma,
St. Louis, MO) into 10 ml dimethyl sulfoxide (DMSO). The
solution to be loaded into the mini-osmotic pumps (Alzet
2001, 1.0 μl/h; Alzet Corp., Cupertino, CA) was made by
taking 2.3 ml unbuffered normal saline (NS), adding 4 μlo f
10 N NaOH (undiluted Fixanal; Riedel-deHaën, Seelze,
Germany), then adding 200 μl stock solution, in that order
to prevent precipitation of drug. The solution to be used for
the loading dose was made by adding 4 μl of stock solution
to 1 ml NS. For vehicle controls, solutions were made with
DMSO, NS and NaOH, as above, but glibenclamide was
omitted. The pumps were filled with a measured volume of
solution (222–238 μl), with the volume determined by the
difference in mass before and after loading. After loading,
the pumps were primed overnight in NS at 37°C with the
outlet of the pump connected to a length of PE60 tubing that
extended above the level of the priming solution, to prevent
H
+ ions from entering the pump chamber. Prior to implant-
ing, the outlet of the pump either was left unconnected, for
immediate start of drug infusion, or it was connected to an
empty catheter (PE60 tubing), 5.5 μl in volume, to obtain a
5.5-h delay in the start of drug infusion [25].
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were carried out to confirm proper loading and functioning
of the pumps. At the end of an experiment (after stroke-
related death or 48 h), the pump was removed from the
animal and function was assessed by assuring proper seating
of the cap, and by measuring residual pump volume. Proper
formulation and correct loading were assessed by measuring
the glibenclamide concentration in the residual solution. The
concentration of glibenclamide in the pump (nominally
200 μg/ml) was measured spectrophotometrically (absor-
bance at 239 nm) [8] and was compared to a standard
solution prepared at the same time and stored in a glass vial.
In one instance, these checks led to the exclusion of one rat
when it was found that the pump had not been properly
loaded.
Stability of Glibenclamide Formulation In Vivo
Experiments were carried out to assess the solubility of
glibenclamide (200 μg/ml in 8% DMSO/NS) at pH 6–8.
Solutions were prepared, centrifuged (15,000 × g for
10 min) and the glibenclamide concentration of the solution
was determined spectrophotometrically (absorbance at
239 nm).
Experiments were carried out with five uninjured rats to
determine the stability of glibenclamide solutions in vivo.
Glibenclamide solutions (2.5 ml of 200 μg/ml in 8%
DMSO/NS) were prepared using 1, 2 or 4 μl of 10 N NaOH
(undiluted Fixanal). These solutions were loaded into
pumps. After priming (with the outlet protected as above),
the pumps (one or two per rat) were implanted. At periodic
intervals, pumps were removed from the animals and the
concentration of glibenclamide in the pump solution was
measured.
Sample Size Calculation for the Model of Stroke
Initial experiments with the model used here suggested that
mortality rates of ~50% and ~20% likely would be encoun-
tered with vehicle vs. glibenclamide treatment. Power anal-
ysis was performed (Power and Precision; release 3.2) for a
two-sample proportion with these rates. It was found that
group sizes of 25–40 would yield 61–82% power of reject-
ing the null hypothesis (α00.05; two-tailed).
Experimental Series and Study Groups
In Series 1, 13 rats underwent MCAo plus rtPA administra-
tion as above; five rats were euthanized at 5 h after onset of
ischemia (the end of the 30-min infusion of rtPA) and eight
rats were euthanized 24 h after onset of ischemia; these
brains were used for immunolabeling experiments. In Series
2, 46 rats underwent MCAo plus rtPA administration as
above; 18 rats were administered vehicle and 18 rats were
administered glibenclamide at 4.5 h after onset of ischemia
(the time of recanalization); ten rats were administered gli-
benclamide at 10 h after onset of ischemia (5.5 h after
recanalization). Of the 36 rats treated at 4.5 h, 16 (eight
vehicle and eight glibenclamide) were euthanized at 10 h,
and the remainder were euthanized at 24 h. Of the rats
treated at 10 h, all were euthanized at 24 h. All of these
brains were used to assess hemispheric swelling. In Series
3–5, rats underwent MCAo plus rtPA administration as
above; these rats were used to examine the effect of vehicle
vs. glibenclamide administered at different times (4.5 or
10 h after onset of ischemia) on preclinical outcomes (mor-
tality, Garcia scores, infarct size at 48 h). In Series 3 (vehicle
vs. 4.5-h glibenclamide), Series 4 (vehicle vs. 10-
h glibenclamide), and Series 5 (vehicle vs. 4.5-h glibencla-
mide), there were 55, 50, and 40 rats, respectively. In each
of these series, the allocation ratio was ~1 vehicle to 2
glibenclamide. All series were carried out by two surgeons
performing the same experiment in tandem, which helped to
control for surgeon variability. The 4.5-h experiment of
Series 3 was repeated after several months as Series 5,
which helped to control for temporal variability. No effect
of administering vehicle at 4.5 vs. 10 h was uncovered,
allowing data from all the vehicle-treated rats to be pooled.
Exclusions
Rats were not enrolled if LDF signals did not show sus-
tained reduction of 75–90% for the 30-min period of mon-
itoring, or if the sustained reduction exceeded 90%. The
latter criterion was implemented due to the exceedingly high
incidence of early death associated with >90% reduction. Of
the 145 rats in Series 3–5, 130 met the LDF inclusion
criteria. Of the 130 eligible rats, 13 were excluded after
treatment allocation as follows (numbers in parentheses
denote the number of rats from the vehicle, 4.5-h, and 10-
h glibenclamide groups, respectively): subarachnoid hemor-
rhage (1,2,0), subdural hemorrhage (1,0,0), premature death
before treatment (2,2,0), no discernable infarct (2,1,0), bi-
lateral infarct (0,1,0), technical problem with the treatment
(0,0,1). Final group sizes were: 51, 41, 25 for vehicle, 4.5-h,
and 10-h glibenclamide treatment, respectively.
Good Laboratory Practice
Care was taken to follow good laboratory practice. Daily
treatment allocation (vehicle vs. glibenclamide) was deter-
mined by one investigator (VG) using coin toss, except
when the need arose to balance enrollment. Another inves-
tigator (SKW) prepared and coded the pumps and syringes
and maintained the log of treatments for use later in decod-
ing, but did not otherwise participate. Two surgeons (NT
288 Transl. Stroke Res. (2012) 3:286–295and OV), both blinded to treatment, independently per-
formed surgeries, but did not participate in outcome evalua-
tions. Preclinical outcomes (mortality, Garcia scores and
necropsies) were determined by a separate investigator
(VY) who was blinded to treatment. Measurements of
TTC-lesion sizes and hemispheric swelling were performed
by another investigator (SI) who was blinded to treatment.
Immunohistochemistry
Rats from Series 1 were used for immunohistochemistry.
After transcardiac perfusion/fixation with 10% neutral buff-
ered formalin and cryoprotection of the brain with 30%
sucrose, cryosections were immunolabeled using goat anti-
Sur1 antibody (1:200; SC-5789; Santa Cruz Biotechnology,
Santa Cruz, CA) and, in some cases, co-labeled with laminin
(1:200; FITC-conjugated; EY Laboratories, San Mateo CA)
to identify microvessels. Alexa Fluor-555-conjugated, spe-
cies appropriate secondary antibody (Invitrogen, Carlsbad,
CA) was used for visualization. Omission of primary anti-
body was used as a negative control. The sections were
coverslipped with polar mounting medium containing anti-
fade reagent and the nuclear dye, 4′,6′ diamino-2-
phenylindole (DAPI) (Invitrogen) and were examined using
epifluorescence microscopy. Previous studies from this lab-
oratory confirmed the absence of labeling in control tissues,
and the specificity of the antibody against Sur1 used here
[21, 23, 25].
Quantitative Immunohistochemistry
Unbiased measurements of signal intensity within regions of
interest (ROI) were obtained using NIS-Elements AR soft-
ware (Nikon Instruments, Melville, NY) from sections
immunolabeled in a single batch, as previously described
[7, 22]. All ROI images for a given signal were captured
using uniform parameters of magnification, area, exposure,
and gain. Segmentation analysis was performed by comput-
ing a histogram of pixel intensity for a particular ROI. For
SUR1, specific labeling was defined as pixels with signal
intensity greater than 2× that of background, and the area
occupied by pixels with specific labeling was used to deter-
mine the percent area with specific labeling (% ROI). ROIs
consisted of rectangular areas, 2.5×6.0 mm that were posi-
tioned to encompass the watershed region of the anterior
and middle cerebral arteries (WAM) and the watershed re-
gion of the posterior and middle cerebral arteries (WPM) (as
delineated in Fig. 1a–d).
Hemispheric Swelling at 10 and 24 h
Rats from Series 2 were used to assess swelling. For rats that
died, the skull containing the brain was immersed in
formalin for 3 days. Survivors were euthanized at 10 or
24 h, perfused with NS then formalin, and the skull con-
taining the brain was immersed in formalin for 3 days.
Subsequently, 2-mm coronal sections of the fixed brains
were prepared and imaged using a flatbed scanner. Images
of six consecutive slices were analyzed using Photoshop
(Adobe) to obtain area measurements of both hemispheres,
which were used to compute hemispheric swelling in per-
cent, a robust measure independent of the fixation procedure
[17].
Functional Outcome
Neurological function was assessed using the modified Gar-
cia score [19], with the only modification being that a score
of 0 was assigned for death. Scores were determined at 24
and 48 h after onset of ischemia. Animals that survived were
euthanized at 48 h.
Infarct Volume
For both rats that succumbed to stroke-related death as well
as those euthanized at 48 h, brains were evaluated to obtain
corrected infarct volumes. Coronal sections, 2 mm thick,
were immersed in 2% 2,3,5-triphenyltetrazolium chloride
(TTC) (Sigma-Aldrich, USA) in NS for 20 min at 37°C.
The TTC-stained sections were imaged using a flatbed
scanner. Images of five consecutive slices were analyzed
using Photoshop (Adobe) to obtain area measurements of
the TTC-negative region, and of the ipsilateral and contra-
lateral TTC-positive regions, which were used to compute
the “corrected” hemispheric infarct volume in percent, a
robust measure independent of the processing procedure
[17].
Statistical Analysis
Calculations were performed using either InStat, version 3.1
(GraphPad Software, Inc.) or OriginPro8 (OriginLab Corp.).
Expression levels of Sur1 at 5 vs. 24 h were analyzed using
Student’st-test. Rates of mortality and of petechial hemor-
rhages were analyzed using a 2×2 contingency table with
Fisher’s exact test. Hemispheric swelling for the four groups
of rats treated at 4.5 h was analyzed using a two-way
ANOVA with the Bonferroni test. Hemispheric swelling
for the single group treated with glibenclamide at 10 h was
compared to swelling in groups treated at 4.5 h using Stu-
dent’st-test. Garcia scores were compared between groups
using the Kruskal–Wallis test with Dunn’s post-hoc compar-
isons. The change in Garcia scores of individual rats be-
tween 24 and 48 h was analyzed using a Wilcoxon matched-
pairs test. TTC-lesion volumes were analyzed using a one-
way ANOVA with Bonferroni post-hoc comparisons. The
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between infarct volume and Garcia score were analyzed
using the Spearman rank correlation.
Results
Sur1 Upregulation
Sur1 was previously shown to be upregulated in various rat
models of stroke [21, 23, 25], but not in the model studied
here with a prolonged time before reperfusion. The study of
tissues harvested 5 h after onset of ischemia (after complet-
ing the IVinfusion of rtPA) showed modest immunolabeling
for Sur1 in the watershed region of the anterior and middle
cerebral arteries (WAM) (Fig. 1a), as well as in the watershed
region of the posterior and middle cerebral arteries (WPM)
(Fig. 1c). Upregulation of Sur1 in watershed regions is
typical [21]. Immunolabeling tissues harvested 24 h after
onset of ischemia showed extensive necrosis in the MCA
cortex (upregulation of Sur1 is not observed in necrotic
tissues [21]), as well as prominent upregulation of Sur1 in
both watershed regions (Fig. 1b, d). As previously reported
[21], much of the upregulation in watershed regions local-
ized to microvessels (Fig. 1e, f). Quantification showed that,
in both watershed regions, Sur1 expression at 24 h was 7- to
11-fold greater than at 5 h (Fig. 1g), consistent with contin-
ued upregulation of Sur1 after recanalization.
Formulation of Glibenclamide
Glibenclamide (adopted US name, glyburide, pKa 0 5.3)
is a weak acid that is sparingly soluble in water, but
whose solubility increase with pH. We measured the
solubility of glibenclamide spectrophotometrically (ab-
sorbance at 239 nm; Fig. 2a)[ 8]a tp H6 –8, when
solutions were prepared at a concentration of 200 μg/
ml in NS containing 8% of the co-solvent, DMSO.
Even with the co-solvent, pH 8 was required to achieve
100% solubility (Fig. 2b).
Fig. 1 Sulfonylurea receptor 1
(Sur1) continues to be
upregulated after recanalization.
a–d Coronal sections of rat
brains immunolabeled for Sur1
5h( a, c)o r2 4h( b, d) after
onset of ischemia; note the
immunolabeling for Sur1 in the
watershed region of the anterior
and middle cerebral arteries
(WAM)( a, b) and the watershed
region of the posterior and
middle cerebral arteries (WPM)
(c, d) that increased with time.
e, f Immunolabeling of WPM
region 24 h after onset of
ischemia shows prominent
upregulation of Sur1 (red)i n
elongated structures that co-
label for laminin (green), con-
sistent with microvessels; nu-
clei labeled with DAPI (blue). g
Quantitative immunohisto-
chemistry showing large
increases in Sur1 expression in
WAM and WPM regions that de-
veloped between 5 and 24 h
after onset of ischemia; five and
eight rats, respectively; **P<
0.01. For all experiments,
MCAo was obtained using an
intra-arterial occluder that was
left in place for 4.5 h, after
which a 30-min infusion of rtPA
(0.9 mg/kg IV) was started
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into an animal is predicted to drift toward neutral pH as H
+
ions from the body enter the drug solution, resulting in drug
precipitating out of solution. The loss of high pH can be
rapid, since H
+ ions are transported though water at a rate ~5
times faster than that of other cations whose diffusion is
governed solely by thermal motion [3, 12]. Preventing the
loss in high pH requires sufficient buffering capacity in the
pump solution, in this case an excess of OH
− ions, to
maintain a stable drug concentration.
We examined the stability of solutions of glibenclamide
inside of pumps implanted into uninjured rats. We found
that a solution of glibenclamide (2.5 ml of 200 μg/ml in 8%
DMSO/NS) prepared with 1 or 2 μl of 10 N NaOH (pH 11.5
or 12, respectively) exhibited a progressive decline in con-
centration (Fig. 2c, filled squares, empty circles). By con-
trast, a solution prepared with 4 μl of 10 N NaOH (pH 12.3)
was stable for 2 days and lost ~20% over 6 days (Fig. 2c,
filled circles). The latter formulation was used for the pre-
clinical experiments described below.
Swelling
Edema and hemispheric swelling were previously shown to
be reduced by glibenclamide [21, 23, 25], but not in the
model studied here or when administered as late as 10 h
after onset of ischemia. First, we measured hemispheric
swelling 10 and 24 h after onset of ischemia in rats admin-
istered either vehicle or glibenclamide at 4.5 h (Fig. 3a–c).
Glibenclamide given at 4.5 h reduced swelling measured at
10 h from 7.8±1.2% to 4.1±1.4%. Glibenclamide given at
4.5 h reduced swelling measured at 24 h from 14.7±1.5% to
8.1±1.3%. Statistical analysis showed that the effects of
both time (progression of swelling between 10 and 24 h)
and treatment (vehicle vs. glibenclamide) were significant
(both P<0.001, by two-way ANOVA).
We also measured hemispheric swelling at 24 h in rats
administered glibenclamide at 10 h (Fig. 3c). We used the
previous data—vehicle-treated rats assessed at 10 h that
exhibited 7.8±1.2% hemispheric swelling—as controls for
this experiment. When glibenclamide was administered at
10 h, swelling at 24 h was only slightly more (8.8±1.1%;
P00.56, by t-test) than at 10 h without treatment, suggesting
that glibenclamide largely arrested the formation of edema
during this period of time. When glibenclamide was admin-
istered at 10 h, swelling at 24 h was significantly different
compared to vehicle-treated rats (P00.005, by t-test).
Mortality
Mortality was previously shown to be reduced by gliben-
clamide [21, 23], but not in the model studied here or with a
treatment delay of 10 h. Mortality was assessed 48 h after
onset of ischemia. For the three groups (vehicle, 4.5 h, and
10 h glibenclamide), mortality was 53%, 17%, and 12%,
respectively (Fig. 3d). Values with glibenclamide adminis-
tered at both 4.5 and 10 h were significantly different from
that in the control group (both P<0.01). Values with gliben-
clamide at 4.5 and 10 h were not statistically different from
each other (P00.7).
Garcia Scores
Garcia scores were assessed 24 h after onset of ischemia.
For the three groups (vehicle, 4.5 h, and 10 h glibencla-
mide), scores were (mean ± SEM) 3.8±0.55, 6.6±0.51, and
8.0±0.52, respectively (Fig. 3e, empty bars). Values with
Fig. 2 Glibenclamide formulation. a Spectrophotometric measure-
ment shows that absorbance at 239 nm is linearly related to the
concentration of glibenclamide solubilized in normal saline supple-
mented with 8% dimethylsulfoxide (DMSO); absorbance due to
DMSO was subtracted. b The solubility of glibenclamide, prepared
as a 200 μg/ml solution in NS supplemented with 8% DMSO, depends
on pH. c The stability over time of glibenclamide solutions (2.5 ml of
200 μg/ml in 8% DMSO/NS plus 1, 2, or 4 μl of 10 N NaOH) placed
inside of an implanted mini-osmotic pump depends on the amount of
buffering capacity included in the formulation; buffering capacity
supplied by the volume of 10 N NaOH indicated; in b and c, spectro-
photometric measurements were made after a 10-fold dilution
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improves outcomes in a
clinically relevant model of
stroke. Hemispheric swelling
imaged at 24 h in rats
administered vehicle (a)o r
glibenclamide (b) 4.5 h after
onset of ischemia; vertical bars
denote the location of midline
structures; the scatter plot (c)
shows the percent hemispheric
swelling at 10 and 24 h in rats
administered vehicle (empty
circles) or glibenclamide at
4.5 h (Glib 4.5 h; filled gray
circles) or 10 h (Glib 10 h; filled
black circles) after onset of
ischemia; 8–10 rats per group;
***P<0.001, pertains to
analysis of the four groups
treated at 4.5 h. d Mortality,
assessed at 48 h, in rats
administered vehicle,
glibenclamide at 4.5 h after
onset of ischemia (4.5 h Glib)
or glibenclamide at 10 h after
onset of ischemia (10 h Glib);
51, 41, and 25 rats in the three
groups, respectively; **P<
0.01; data at 4.5 and 10 h are
not statistically different from
each other (P00.7). e Garcia
scores, assessed at 24 h (empty
bars) and 48 h (gray bars), in
rats administered vehicle,
glibenclamide at 4.5 h after
onset of ischemia (4.5 h Glib),
or glibenclamide at 10 h after
onset of ischemia (10 h Glib);
same rats as in d;* * P<0.01;
***P<0.001; data at 4.5 and
10 h are not statistically
different from each other (P>
0.05). f Representative infarct
visualized using TTC (left), and
comparison of infarct volumes
measured at 48 h in rats
administered vehicle or
glibenclamide at 4.5 or 10 h
after onset of ischemia, as
indicated (P00.5)
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0.001) were significantly different from that in the control
group. Values with glibenclamide at 4.5 and 10 h were not
statistically different from each other (P>0.05).
Garcia scores were assessed 48 h after onset of ischemia.
For the three groups (vehicle, 4.5 h, and 10 h glibencla-
mide), scores were (mean ± SEM) 3.8±0.62, 7.6±0.70, and
8.4±0.74, respectively (Fig. 3e,g r a yb a r s ) .V a l u e sw i t h
glibenclamide administered at 4.5 and 10 h were significant-
ly different from that in the control group (both P<0.001).
Values with glibenclamide at 4.5 and 10 h were not statis-
tically different from each other (P>0.05).
In vehicle-treated rats that survived 48 h with a Garcia
score >1, the Garcia score at 48 h was negatively correlated
with the reduction in LDF signal recorded at the onset of
ischemia (Spearman r0−0.62; P<0.01). By contrast, in rats
treated with glibenclamide at 4.5 h, this correlation was lost
(Spearman r00.28; P00.1). The significant negative corre-
lation in the vehicle-treated group may have been due to
continued brain swelling, which would be expected to be
worse with a more severe ischemic insult. The loss of
correlation with glibenclamide would be consistent with
reduced swelling in this group (Fig. 3a–c)[ 21, 23].
For rats that survived the first 24 h (Garcia score >0), we
also examined the changes in Garcia scores that occurred
subsequently. In vehicle-treated rats, 4/28 survivors (14%)
died between 24 and 48 h, and overall Garcia scores were
unchanged (6.9±0.5 and 6.9±0.7 at 24 and 48 h, respec-
tively; P00.61). In rats treated with glibenclamide at 4.5 or
10 h, 3/59 survivors (5%) died between 24 and 48 h, and
overall scores improved between 24 and 48 h, from 8.0±0.2
to 8.9±0.4 (P<0.01).
Infarct Size
TTC-infarct volumes were assessed 48 h after onset of
ischemia (Fig. 3f). For the three groups (vehicle, 4.5 h,
and 10 h glibenclamide), corrected infarct volumes were
(mean ± SEM): 30.8±2.0%, 29.8±2.3%, and 26.7±2.8%,
respectively (P00.5).
In vehicle-treated rats that survived 48 h with a Garcia
score >1, the Garcia score at 48 h was negatively correlated
with infarct volume (Spearman r0−0.81; P<0.0001). By
contrast, in rats treated with glibenclamide at 4.5 h, this
correlation was lost (Spearman r0−0.34; P00.06).
Hemorrhagic Transformation
Confluent areas of hemorrhagic transformation of an ische-
mic region, as often reported with 10 mg/kg rtPA in rats
[14], were not seen with the dose of 0.9 mg/kg used here,
but in some rats, discrete petechial hemorrhages, 0.4–1 mm,
were observed. For the three groups (vehicle, 4.5 h, and 10 h
glibenclamide), petechial hemorrhages were identified in 6/
51, 6/41, and 3/25 rats, respectively (P00.76, 0.99, respec-
tively, compared to control). In all cases, a single petechial
hemorrhage was located in the caudate; in two of the rats, a
second petechial hemorrhage also was located in the cortex.
Validation of Drug Delivery System
To confirm proper functioning of the pumps in the preclin-
ical studies reported above, frequent periodic checks were
made of the volume of solution remaining in the pump at the
time of either stroke-related death or planned euthanasia
(48 h). In 50 cases tested, the residual volume was appro-
priate for the time of removal of the pump from the animal,
given the measured volume that was loaded (222–238 μl),
the time when priming was started, and the nominal rate of
delivery of 1 μl/h. The same samples also were tested to
confirm the presence of vehicle (20 pumps) vs. drug (30
pumps), as well as the concentration of glibenclamide in
solution. Measurements of glibenclamide solutions removed
at ~24 and 48 h showed values of 94±1.3% and 86±1.8% of
the expected concentration, respectively (16 and 14 pumps
each), which accorded well with the previous measurements
in Fig. 1c.
Discussion
There are two important new findings in the present study.
First, our data indicate that glibenclamide is highly effective
when administered as late as 10 h after onset of ischemia.
Previous work showed efficacy of glibenclamide out to 6 h
[23]. However, recent elucidation of the molecular mecha-
nism responsible for transcriptional upregulation of the
Sur1-channel [30], combined with the fact that brain swell-
ing after ischemia takes hours to develop [13, 20], suggested
that the treatment window for glibenclamide might exceed
6 h. This was confirmed here, with data indicating undimin-
ished efficacy out to 10 h. Previous work with rat models of
MCAo showed treatment efficacy (infarct volume or neuro-
logical function) for a variety of agents when treatment was
initiated at 10 h after onset of ischemia (ischemic insult: 2-
h MCAo [28, 29]), at 12 h (ischemic insult: 1-h [32], 1.5-
h[ 10], and 2-h [27] MCAo), and at 18 h (ischemic insult:
20-min MCAo [10]). To our knowledge, no agent other than
glibenclamide has shown treatment efficacy on mortality
from malignant edema and on neurological function when
administered at 10 h in a model with 4.5-h MCAo.
Secondly, in the model used here, glibenclamide appeared
to dissociate functional outcomes (mortality and Garcia
scores) from infarct volumes. Although previous reports that
examined either permanent occlusion [18, 25] or a shorter
ischemic time (105 min) [25] indicated that glibenclamide
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changed by treatment. The 4.5-h duration of ischemia used
here apparently was associated with a maximum ischemic
insult when measured at 48 h, leaving little opportunity for a
reduction in infarct volume by drug. Many reports indicate
that 3 h of mechanical occlusion produce maximum infarct
volumes when measured 48 h later, and that longer occlusion
times do not increase infarct size further [4, 31]. Similarly, in
rat models, administration of rtPA (10 mg/kg) is ineffective in
reducing infarct volume when given more than 2–4ha f t e r
onset of ischemia [4, 16, 33]. Together, these studies indicate
thatit should not be surprisingthatinfarct volumeswould have
been similar in vehicle vs. glibenclamide groups. However,
despite the same infarct volumes, functional outcomes were
significantly better with glibenclamide, indicating that some
factor other than infarct volume determined functional out-
come. The other factor likely was edema or brain swelling.
Prior studies showed that edema and brain swelling are signif-
icantly ameliorated by glibenclamide [18, 21, 23, 25], as was
reaffirmed in the present study in a different model of stroke.
An important goal of preclinical stroke studies is the
development and use of clinically relevant models that
may be helpful in predicting the outcome of clinical trials.
Numerous models of ischemic stroke in rats have been
described, but few precisely mimic clinical stroke [5]. Truly
permanent occlusion, as studied in rats with occluders per-
manently positioned at the ICA bifurcation, rarely occurs in
humans because of eventual spontaneous recanalization.
Also, nearly all transient ischemia models studied in rats
utilize relatively short ischemia times in order to preclude
fatal swelling. In the model we studied, recanalization was
obtained by removing the occluder at 4.5 h, simulating intra-
arterial mechanical clot retrieval [6]. At the same time, we
administered rtPA at the latest time and at the dose used in
humans (0.9 mg/kg IV) [2, 9]. Although this dose is
expected to be minimally thrombolytic in rats [11], it was
important to avoid the excess toxicity associated with
10 mg/kg rtPA [9] in order to maintain relevance to humans.
In addition, use of a sub-thrombolytic dose served to mimic
the situation frequently encountered in humans wherein
administration of rtPA does not lead to timely recanalization
or reperfusion [1, 26]. Finally, our outcomes were focused
on improvements in mortality, brain swelling and neurolog-
ical function, rather than a reduction in lesion volume,
because of the indisputable clinical impact of the first
three—rtPA, currently the only drug approved for use in
stroke, was approved based on its demonstrated ability to
improve functional outcomes, not because it reduces lesion
volumes. These considerations led to the model described
here, which we believe to be highly relevant clinically.
An important limitation of the present study is that we did
not examine the effect of occluder removal plus rtPA ad-
ministration at 4.5 h on LDF signals or other measures of
cerebral blood flow. As a result, we do not know the status
or timing of cerebral reperfusion in this model. In our
previous study [23], removing the occluder at 6 h (no rtPA
administered) often resulted in delay of reperfusion (judged
by LDF signals) by up to 2 h, consistent with development
of thrombosis during occlusion, and delayed spontaneous
thrombolysis after occluder removal. It is likely that in the
model studied here, thrombolysis was eventually achieved,
but when this occurred, in which vessels it occurred, and
whether it occurred too late to salvage tissues, is not known.
Anotherlimitationofthe presentstudyisthatwedid notstudy
survivors beyond 48 h. However, our data indicate that rats
administered glibenclamide, but not vehicle, improved signif-
icantly between 24 and 48 h. Also, our previous experience
with the Garcia scoring system showed that rats exhibiting
scores of 6 or better at 48 h rarely die and almost always
improve functionally [23]. Thus, it seems unlikely that the
beneficial effects of glibenclamide observed here at 48 h
would have been negated by longer observation.
In summary, we describe a rat model of stroke that was
designed to mimic several aspects of the human condition,
including severe ischemia (75% < reduction in LDF signals
≤90%), abrupt recanalization at 4.5 h, administration at 4.5 h
of the dose of rtPA used in humans, and evaluation of
clinically relevant endpoints. The insult produced, com-
bined with other features of the model, yielded a severe
injury with high mortality and poor functional outcome.
Using this model, we demonstrated that outcomes (swelling,
mortality, and neurological function) were significantly im-
proved when low-dose glibenclamide was administered at
either 4.5 or 10 h after onset of ischemia.
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